Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis
Laura Bukavina, Spencer Bell, Vignesh T. Packiam, Marc C. Smaldone, Philip H. Abbosh, Robert G. Uzzo, Alexander Kutikov, Andres Correa, Diana Magee
Topics & Concepts
DocetaxelGemcitabineMedicineCost effectivenessOncologyBladder cancerInternal medicineCost-effectiveness analysisCancerRisk analysis (engineering)Bladder and Urothelial Cancer TreatmentsImmune responses and vaccinationsUrinary and Genital Oncology Studies